RxDoctor Payments Data

William Chapman, DO

Neurology · Cincinnati, OHNPI 1184129512

Payments from drug & device makers

$182,679in general payments, 2019–2025

Across 156 payments — averaging $1171.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$134K
  • Biogen$19K
  • TG Therapeutics, Inc.$12K
  • Amgen$7K
  • AbbVie$5K
  • EMD Serono, Inc.$4K
  • plus $2K from 5 others

What the payments were for

  • Consulting fees$12,02223%
  • Speaking & faculty fees$32,38362%
  • Travel & lodging$2,3134%
  • Food & beverage$5,60111%
  • Education$3001%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis80$133,589
Biogen19$19,269
TG Therapeutics, Inc.14$11,793
Amgen(2 entities)11$7,355
AbbVie5$5,166
EMD Serono, Inc.9$3,825
AstraZeneca8$807
E.r. Squibb & Sons, L.L.C.3$340
Sanofi3$336
Genentech USA, Inc.3$175
Vanda Pharmaceuticals Inc.1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$182,679 in reported general payments places this provider in the 85th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$22,301
Medicare patients
110
Services billed
313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab89$784,155
TecfideraDimethyl Fumarate20$175,993
CopaxoneGlatiramer Acetate24$131,406
VumerityDiroximel Fumarate14$116,871
ZeposiaOzanimod Hydrochloride12$107,221
Avonex Pen (4 Pack)Interferon Beta-1a11$89,593
Dalfampridine ErDalfampridine166$40,322
Lacosamide66$5,402
Gabapentin169$3,370
Baclofen153$3,105
Pregabalin67$2,076
Carbamazepine ErCarbamazepine13$1,965
Teriflunomide20$1,637
Mycophenolate Mofetil18$970
Tizanidine Hcl25$760

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera, Vumerity$19,269$292,86434 claims
E.r. Squibb & Sons, L.L.C.Zeposia$340$107,22112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 702 neurology providers in Ohio.

Other neurology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →